The Meakins-Christie Laboratories is a leading pulmonary research centre located in Montreal (Canada) and affiliated with McGill University, one of the top ranked universities in the world. Our overall mission is to better understand the pathobiology of respiratory disorders across the lifespan. The ultimate goal of our efforts is to drive innovations in respiratory disease prevention, diagnosis, and therapy. Research is focused around five primary themes: Chronic Airways Disease, Lung Injury and Infection, Neuromuscular Dysfunction in Respiratory Diseases, Sleep-disordered Breathing, and Lung Cancer. Our faculty of world-class researchers work within the Translational Research in Respiratory Diseases Program at the Research Institute of the McGill University Health Centre.
In the News
Lauzon lab members receive the second dose of the COVID-19 vaccine. Remember, mandatory vaccination is required by Nov 15, 2021.
Dr. Mazer has been awarded the inaugural Donald Stark Award for Excellence in Leadership in the Canadian Allergy Community.
Dr. Ben Geboe is the recipient of the 2021-2022 Dr. Margaret Becklake Fellowship in Respiratory Research.
Dr. Martin received the CTS 2021 Honorary Lecture Award in recognition of his contributions to respiratory medicine.
Dr. Dao Nguyen and colleagues discuss antimicrobial resistance and the new McGill AMR Centre
Dr. Jean Bourbeau is a newly elected Fellow of the Canadian Academy of Health Sciences, a prestigious honor in health sciences.
Congratulations to Dr. Stefano Nava, a Meakins-Christie alumnus who received the 2021 ERS Presidential Award.
Congratulations to Dao Nguyen, Irah King, Nicole Ezer, Andrea Benedetti and Dennis Jensen on their CIHR Project Grants!
Congratulations to Dr. Tania Janaudis-Ferreira on successfully receiving a grant from the 2021 CDTRP Research Innovation Grant Competition.
Susan Westfall, Postoc Fellow in the lab of Dr. Irah King, will present on October 18, 2021 @ 9 am, a Work-in-Progress Seminar.
Dr. Claudia dos Santos will talk on translational studies of Mesenchymal Stromal Cell (MSC) therapy for severe sepsis on October 25, 2021 at 9 am.
Our 2021-2022 activities are starting this September, including our WIP, Seminar Series, and the Journal Club